Yano Motoki, Sasaki Hidefumi, Moriyama Satoru, Hikosaka Yu, Yokota Keisuke, Masaoka Akira, Fujii Yoshitaka
Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Interact Cardiovasc Thorac Surg. 2011 Jul;13(1):21-4. doi: 10.1510/icvts.2010.264036. Epub 2011 Mar 30.
In advanced stage thymomas, recurrence is not uncommon but prognostic factors in recurrent thymoma have not been determined and standardized treatment for recurrence has not yet been established. A retrospective analysis was conducted on 24 thymoma patients who underwent treatment for recurrence in our institution to determine the prognostic factors for overall survival. Recurrence of thymoma appeared 11.6-109.6 months after the primary operation (34.6±25.7 months). Pleural disseminated recurrence was common (n=21) as the primary recurrent lesions. Single or combined modality therapy was performed in 19 patients; surgical resection in 12, radiotherapy in 10, and chemotherapy in six patients. A third surgical resection was performed in two patients. There was no difference in overall survival between the groups with or without treatment nor in those with or without resection. Old age and chemotherapy were factors for poorer prognosis. Patients with one or two recurrent lesions detected on CT examinations showed better prognosis. Prognosis in thymoma patients with recurrence was reviewed in the present study. Patients with a small number of recurrent lesions showed better prognosis irrespective of the treatment.
在晚期胸腺瘤中，复发并不少见，但复发性胸腺瘤的预后因素尚未确定，针对复发的标准化治疗也尚未确立。对我院24例接受复发性胸腺瘤治疗的患者进行回顾性分析，以确定总生存的预后因素。胸腺瘤复发发生在初次手术后11.6 - 109.6个月（34.6±25.7个月）。胸膜播散性复发常见（n = 21），为主要复发灶。19例患者接受了单一或联合治疗；12例行手术切除，10例行放疗，6例行化疗。2例患者接受了第三次手术切除。接受治疗组与未治疗组、接受切除组与未切除组的总生存无差异。高龄和化疗是预后较差的因素。CT检查发现一两个复发病灶的患者预后较好。本研究对复发性胸腺瘤患者的预后进行了回顾。无论治疗情况如何，复发病灶数量少的患者预后较好。
